NetworkNewsWire Editorial Coverage: Last year changed the world in unexpected ways, as people and businesses looked to keep moving forward in the face of a global coronavirus pandemic. In many instances, COVID-19 simply accelerated the inevitable, such as trends towards digitization while lockdown orders were in place. Perhaps the most significant example was in education, where students from grade school to college went 100% virtual for the first time in history. Education technology, or edtech, is a hot trend that, even as the pandemic wanes, isn’t showing any signs of slowing among today’s generation of digitally native learners, as evidenced by analyst forecast and upstarts such as Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) (Profile), which is partnering with juggernaut Microsoft Corporation (NASDAQ: MSFT) for solutions to transform higher education. As it happens, Facebook Inc. (NASDAQ: FB), Alphabet Inc. (NASDAQ: GOOGL) and Coursera Inc. (NYSE: COUR) have also dedicated considerable resources reimaging education and democratizing learning for everyone, everywhere.

• The global edtech market is estimated at $106 billion and forecast to expand at a 19.9% CAGR through 2028.
• Nextech AR Solutions lists numerous leading educational institutions as clients and partners.
• The company recently launched its EdTechX platform, with customers already coming on board.
• EdTechX quickly achieved co-sell ready status with Microsoft, a partnership reserved for proven companies with highest-quality tech.

EdTech: One-Third of a $340 Billion Market

Big money has gotten behind edtech, catalyzing double-digit growth. Market analysts at Grand View Research estimate the global education technology market at $106 billion for 2021, up from about $86 billion in 2020, and on track to grow 19.9% annually through 2028 as digital technology improves access to education. The movement is global, including emerging markets such as Africa where tech is filling holes in learning.

Remote learning is one thing, but the future of education involves the marriage of remote learning to next-generation technology, including augmented reality (“AR”). With AR, computer-generated objects are seen on a screen in real time, a technique that helps students learn in a more interactive and engaging environment. Grand View sees the global AR market growing at a spectacular 43.8% compound annual growth rate to $340.2 billion by 2028.

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) is on the cutting edge of the markets as a developer and operator of AR platforms that transports 3D product visualizations, human holograms and 360° portals. The company curates its products to a diverse array of blue-chip customers, including Budweiser, JNJ and IBM, by altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.

Nextech solutions have been used in more than 4,100 events that have been attended by more than 10 million people. Of particular interest is the company’s newly launched augmented learning platform and hybrid and virtual events products that are prime to disrupt a higher education market ripe for innovation. The platform, branded EdTechX, is gaining immediate traction.

Bring the Lab to the Kitchen Table

Nextech has already planted its flag in the university and college markets. Ryerson University, Carnegie Mellon University, University of South Florida, Université Laval (in Quebec City, Quebec), and UN Educational, Scientific and Cultural Organization (“UNESCO”) are only a few of those that trust Nextech for their needs. EdTechX is a comprehensive education product for global customers combining enterprise-scale video streaming, integrated assessments, augmented reality holograms and data analytics.

Applications abound for Nextech where it can provide virtual learning labs, digital courses and poster sessions, live demos and collaborations, Q&A sessions, teaching tools, downloadable course content and more, including uses outside the classroom such as homecoming events, convocations and career fairs. Using its AR and hologram technologies, Nextech worked with Ryerson to develop customized virtual labs for a several different science programs of the university.

Partnered with Microsoft for Sales

Nextech’s EdTechX is a new offering; the company just launched its LiveX platform built on Microsoft Azure this month. Ryerson, Carnegie Mellon and Black Student Fund have already implemented EdTechX into their daily operations. While impressive, this is just scratching the surface, where in the United States alone there are upwards of 5,300 higher education institutes that enroll more than 19 million students.

In addition, EdTechX has achieved Microsoft’s co-sell ready status, a milestone that should not go understated. A Microsoft co-seller process includes building demand, sales planning, sharing sales leads, accelerating partner-to-partner empowered selling and delivering marketplace-led commerce. This is the top tier for Microsoft partners, and qualifying puts Nextech in an elite group of global independent software vendors (“ISVs”) that are transforming industries.

A Microsoft co-seller agreement allows Nextech to work with Microsoft sales teams to actively fulfill customer needs globally, which speaks to the quality of EdTechX and Nextech, as Microsoft reserves this type of relationship exclusively for companies with outstanding technology and a proven customer track record.

“Nextech AR Solutions is helping education institutions digitally transform the way educators teach and the way students learn, by enabling remote experiential learning through EdTechX,” said Nancy Teodoro, education partner lead at Microsoft Canada.

Clients in High-Growth Markets, CEO (Keeps) Buying

In September, the Bureau of Labor Statistics released its projections for industry growth and contraction for the next decade. As it happens, Nextech is in the catbird’s seat considering that Nextech AR and digital experience platform services customers represent eight out of the top 10 for fastest-growing industries.

Investors always love to see “skin in the game” in the form of management laying out their own cash to buy shares of stock. To that end, Nextech CEO Evan Gappelberg remains “extremely excited about our business prospects,” proving that optimism by yet again increasing his ownership position. At the end of May, Gappelberg exercised warrants for another $186,650, marking his seventh purchase in the last 18 months. In that time, the Nextech chief executive has bought 1.54 million shares, increasing his total holdings to 9.86 million shares. Gappelberg explained his outlook on the company in depth during a recent Nextech presentation at the 2021 LD Micro Invitational.

Sub5

Regardless of its $100 billion market status, the edtech market is still in its nascency. So is AR for that matter. The beauty is that they are emerging into an audience of young adults that have known nothing but the digital world, which virtually ensures mass adoption to rapidly re-shape the higher education landscape and new brand of pedagogues in the coming years.

Microsoft Corporation (NASDAQ: MSFT) has unprecedented scale and influence to play an important — and profitable — role in the global adoption of digital education. In aggregate, millions of companies and consumers (students, teachers, schools, etc.) will leverage the Azure architecture. The company is an education advocate and active in promoting online classrooms through its Microsoft Teams for Education and providing free access to a litany of its online education and learning tools.

Facebook Inc. (NASDAQ: FB) is much more than just a social media platform and ad-revenue generating behemoth. While it doesn’t take a conventional route, the company is active on many different levels in the edtech space, including its Oculus VR (virtual reality) unit that it acquired in 2014 for approximately $2 billion. Doing what it does best, Facebook uses tech to disseminate information, albeit for peer-to-peer programs for educators, policy protocols, building communities. Facebook also provides specific content to teach digital marketing to students at all levels of higher education.

Alphabet Inc. (NASDAQ: GOOGL) is the parent of Google for Education, which works with many higher education universities on different verticals in addition to offering its Google Workspace products. Many may think of just search and ads when it comes to Google, but its education unit has many successes to its name, including working with the University of South Carolina to use cloud computing to study climate change and Brown University to use VR to recreate colonial history.

Coursera Inc. (NYSE: COUR) is new to the public markets, completing its IPO on March 31 to raise $520 million by offering 15.73 million shares at $33 each. The Silicon Valley-based pure-play EdTech company offers people access to online courses and thousands of degrees from a spate of universities. Business boomed during the pandemic, with revenue climbing 59% to $293 million in 2020, although net losses grew year-over-year by $20.1 million to $66.8 million.

As it does in so many other components of life, technology has improved the value chain of education. The benefits are overarching, to say the least, and level the playing field for students of all ages in all geographic regions wishing to receive any degree that typically would have only been possible via on-campus schooling.

For more information about Nextech AR Solutions, please visit Nextech AR Solutions.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

The shift towards electrification and clean energy is not limited to only automakers and electric vehicle (“EV”) makers. 7-Eleven Inc., an Irving, Texas-based convenience retailer with hundreds of stores across the United States and Canada has unveiled plans that will push the chain to the forefront of sustainability. In a move that will accelerate its environmental conservation goals by years, the convenience giant has announced that it plans to construct a minimum of 500 EV charging stations at 250 stores in the United States and Canada by the end of 2022.

The 500 DC Fast Charging (“DCFC”) ports are expected to be a major addition to the 22 already existing charging stations installed at 14 7-Eleven stores in 14 countries. Once the installation of these DCFC ports is complete, the Texas-based compay claims that it will be among the most widespread and compatible EV fast-charging networks in America, rivaling any such systems that have been installed by most retailers in the country. Aside from high upfront costs, range anxiety is one of the main deterrents against going green for most drivers, and such a network of fast-charging infrastructure would see the convenience giant attract tons of EV drivers who would like to recharge while on the road.

According to company president and CEO Joe DePinto, 7-Eleven is always striving to come up with novel ideas and develop new technologies to serve their customers better. By installing 500 fast-charging stations, the company aims to make charging much more convenient for their customers and to play a role in the widespread adoption of alternative energy vehicles. It is the right thing to do, DePinto says, and this sentiment echoes 7-Eleven’s efforts to become a leader in green energy and sustainability, especially in the retail sector.

The Texas-based retailer had previously pledged to reduce its CO2 emissions by 59% by 2030, but it managed to achieve part of this goal nearly eight years in advance of its planned schedule, reducing its carbon emissions by 20% in 2019. Additionally, 7-Eleven has stated that a minimum of 800 of its stores in Texas and in excess of 300 stores in Illinois are powered by wind energy. An additional 150 stores in Virginia run on hydroelectric power while 300 of its stores in Florida rely on solar power.

7-Eleven operates more than 79,000 convenience stores worldwide, with more than 10,000 of them in North America. So while its efforts at sustainability may seem like a drop in the ocean, this is a great start, and it is certainly more effort than any other retailer has put into reducing its carbon footprint.

As industry actors such as Net Element (NASDAQ: NETE) look to increase their EV offerings, the complementary work being done by 7-Eleven and other corporates could make EV adoption swifter than initially expected.

NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

• UUUU is focused on building fully integrated, rare earth supply capabilities
• Carester is recognized as leading authority, global consultants on rare earth supply chains
• Energy Fuels committed to restoring critical U.S. domestic rare earth capabilities

In its ongoing commitment to developing its rare earth element (“REE”) business, Energy Fuels (NYSE American: UUUU) (TSX: EFR) is working with Carester SAS, a leading global expert on rare earth separation (https://ibn.fm/lb61d). UUUU is working with Carester to conduct a scoping study for the development of a solvent extraction REE separation circuit at Energy Fuels’ White Mesa Mill in Utah.

“Energy Fuels is absolutely focused on building fully integrated rare earth supply capabilities at our White Mesa Mill in the coming years, and we are pleased to have Carester on the team to support our efforts,” said Energy Fuels president and CEO Mark S. Chalmers, President and CEO of Energy Fuels. “Since we began evaluating the potential to produce rare earth products in late 2019, Energy Fuels has partnered with only the best global experts at every opportunity, and the agreement with Carester is just another example of how our company is advancing our strategy on the complete REE production sequence.”

Last year Energy Fuels announced its intent to explore the potential of producing separated REE oxides, REE metals, REE alloys and other value-added REE products at its White Mesa Mill with the objective of creating a fully integrated U.S. REE supply chain in the coming years. Partnering with Carester represents a key component of that development.

Energy Fuels and Carester will be evaluating the next steps as the company moves forward with its planned development of REE separation capabilities at the White Mesa Mill. Energy Fuels anticipates using existing equipment and infrastructure as much as possible as it works to create a continuous, integrated and optimized rare earth production sequence. Part of the study calls for Carester to evaluate the mill’s current monazite leaching process; the Carester team will also prepare an REE separation flow sheet, calculate capital and operating expense estimates, analyze where new technologies need to be incorporated and even recommend equipment vendors.

Energy Fuels opted to partner with France-based Carester because its team is recognized as a leading authority and global consultants on rare earth supply chains, offering invaluable insight and expertise in designing, constructing, operating and optimizing REE production facilities globally.

“Rare earth extraction, separation and purification can be complex. We believe that our extensive in-house processing experience, combined with Carester’s expertise, places the company in an excellent position to successfully and cost effectively help to restore critical domestic rare earth capabilities in the USA at the White Mesa Mill,” Chalmers said. “As more clean energy and advanced technologies are deployed, more rare earth products will be required.

However, technologies are only clean if every step in the supply chain from the mine to the final consumer product is clean,” continued Chalmers. “An electric vehicle is not green if the raw materials that go into the vehicle are not responsibly produced. The U.S. has the highest standards for safety, efficiency and environmental responsibility in the world when it comes to mining, processing, refining and manufacturing. Energy Fuels is working towards establishing a clean and green U.S. option for manufacturers who demand the highest standards in their rare earth raw materials.”

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Investing in medicinal psychedelic research in the recent past was considered risky. Now, however, financiers and entrepreneurs are injecting money into the development of psychedelic therapies for behavioral and mental health issues. Despite this, one of the biggest public financiers of medical research in the world — the National Institutes of Health — is yet to do so.

The organization’s absence in psychedelic medicine may potentially be slowing the development of new innovative treatments as well as preventing researchers from entering the field.

Records show that various human populations have used psychedelics such as psilocybin, mescaline, MDMA, LSD, ibogaine, DMT and ayahuasca, just to name a few, for centuries. However, these substances made their way into Western medicine only recently, starting to show up in the ’50s and ’60s.

During this time, psilocybin and LSD were utilized in the enhancement of psychotherapy, before being classified as Schedule I drugs in the ’70s. This made their use illegal in both recreational and medical realms, with research on the substances being halted as well. However, a few years ago, philanthropic organizations and researchers begun conducting research on these substances once more, which led to the discovery of the various potentials that psychedelics possess.

For instance, results published earlier this year found that MDMA, which is commonly known as ecstasy, is effective in the treatment of PTSD. Many are hopeful that the U.S. Federal Drug Administration (“FDA”) may soon approve the use of MDMA-assisted psychotherapy.

These findings and many others have prompted venture capital firms to increase their investments in psychedelic biotech startups, with data showing that investments grew from $1 million in 2017 to more than $300 million in 2021. This is why it’s surprising that the National Institutes of Health (“NIH”) is yet to finance any research work in the field, despite the support for medicinal psychedelic research in the psychiatric field. The organization’s reluctance will continue to hinder psychedelic medicine progress, even with private financing materializing.

Apart from this, the institute’s lack of involvement is also limiting biopharmaceutical firms that depend on it to finance high-risk foundational research, which would enable them to center on drug development. If the NIH did decide to fund psychedelic research, it would allow the industry to develop psychedelic medicines for various conditions, including personality disorder, vegetative states and functional neurological disorder. However, pilot data is lacking.

Fortunately, the NIH seems to be changing its course, having recently awarded its first grant for medicinal psychedelic research earlier in April.

As the interest of the NIH in psychedelics grows, its work will add onto the contributions being made by publicly traded firms such as Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), which are looking to use psychedelics to revolutionize the way mental health conditions are treated.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

• Ehave announced it will utilize BRSF’s tech in an upcoming ketamine clinical study
• BRSF’s tech will make it possible to correlate biomarkers for the identification of chronic pain, depression, PTSD, bipolar disorder, and more.
• The data from this clinical trial has the potential to provide longitudinal insights that can link brain analysis and psychedelics

Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is on a mission to modernize brain diagnostics with cutting-edge tech that bridges the widening gap in access to quality care. The company’s technology will be part of a ketamine clinical study conducted by Ehave, Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. To read Ehave’s full announcement regarding the Ketamine Clinical Trial, go to https://ibn.fm/VMu6o.

Ehave is a leading provider of digital therapeutics for the psychedelic and mental health sectors. The company’s primary goal is to improve standard care with digital therapeutics to prevent or treat brain disorders or diseases. By partnering with BRSF, they will leverage both data and AI to correlate biomarkers to identify chronic pain, depression, PTSD, bipolar disorder, general anxiety, ADHD, and schizophrenia.

The trial will begin the second half of 2021 and will need to enroll 35 patients. Ehave will be studying the effect of ketamine as a treatment for major depression while assessing the candidate therapy’s safety and tolerability.

Mental health disorders, in the wake of Covid-19, are on the rise. Depression alone affects over 264 million worldwide, and drug overdoses have risen 42% since the pandemic began.

“Ehave’s goal,” stated Alfred Farrington II, CIO of Ehave, “is to help practitioners make more informed decisions about mental health care. We believe the data from this clinical trial will provide longitudinal insights that can link brain analysis and psychedelics.”

Using BRSF’s technology, Ehave will be able to brain map the volunteer patients and show changes in the neuroplasticity of the brain areas impacted by the treatment. This study has the potential to create new forms of treatment for chronic mental health disorders.

BRSF’s neurological devices, NeuroCap(TM) and NeuroEEG(TM) are portable, clinical-grade, cost-efficient, easy-to-use, and allow for long-term monitoring. In addition to these benefits, BRSF’s technology is ideal for clinical studies because of the company’s AI-assisted diagnostic analysis that increases the efficiency, consistency and accuracy of the data collected.

Ehave is the newest to join the quickly expanding list of clinical studies that have taken advantage of BRSF’s next-generation technological solutions for the neurology market.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Most extensive research to date reports significant neurological problems in patients who suffered from so-called long-haul COVID-19
• Neurological issues range from mild to more severe such as cognitive impairment, which affects around 20% of these patients
• BRSF appears poised to be part of the solution as long-haulers need monitoring so that doctors can assess if they have neurological disorders

The neurological and psychiatric aftermath of COVID-19 has been reported, but adequately assessing the effects of the disease on brain health still remains a challenge. A new preprint analysis, representing one of the most extensive studies of neuropsychiatric symptoms among COVID-19 long-haulers, reports that patients who have been sick with COVID-19 for more than three weeks experience cognitive impairment at least six months after the infection (https://ibn.fm/OSDQx). Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, is poised to provide brain monitoring capabilities to enable clinicians to study the brain wave activity of patients with neurological conditions.

So-called long COVID has gained momentum over the past year as some patients reported persistent neurological and psychiatric manifestations after their initial infection. The extensive research studied nearly 19,000 adult patients across 51 studies, discussing evidence indicating a potential relationship between COVID-19 and persistent neurological problems. These problems could range from milder symptoms, including headaches, loss of sense of smell and taste, and fatigue, to more severe conditions, including sleep disorders, pain, and cognitive impairment such as brain fog leading to memory loss or difficulty concentrating or making decisions.

The study found that brain fog affects 20% of Coronavirus long-haulers, while 27% of them reported insomnia, and 24% reported fatigue, both of which researchers believe could stem from neurological issues, although that might not be the only possible cause. Brain fog can have varying impacts on patients; for some, it may be life-altering, while for others can be a minor inconvenience.

However, diagnosing long-term COVID-19 symptoms remains a challenge as doctors are still learning the underlying mechanisms of how the virus works. For example, without knowing how long these neurological symptoms last, doctors are not able to classify them as neurological disorders or even chronic illnesses. The researchers conclude that doctors will need to track long-haulers to decipher whether they have neurological disorders after they suffered and survived Coronavirus infection.

As a growing body of research indicates, the long-term outlook for COVID-19 patients is still uncertain. Long haul Covid-19 survivors will need ongoing medical help to track and manage the long-term impact of the virus on their health, including brain health. That’s where Brain Scientific’s unique technology can help.

The Company has developed NeuroEEG(TM), a portable, wireless device that can record and display the patient’s electrical brain activity that works together with the NeuroCap(TM) — a hospital-grade disposable EEG headset that comes in sizes for adults and pediatric patients.  Brain Scientific is working on developing another revolutionary technology — Brain E-Tattoo(TM), a minimally invasive four-channel implant or imprint tattoo designed for long-term brain wave activity monitoring even beyond the clinical setting. It can provide access to long-term neurological studies, potentially helping identify root neurological problems.

More than a year into the pandemic, it remains a challenge to understand the immediate effect of the virus on brain health, with no definite answer regarding the long-term impact either (https://ibn.fm/xNJLl). The scientific world is only starting to truly grasp the effect of COVID-19 on the brain. Brain Scientific appears poised to be a key player providing unparalleled technology that will potentially contribute to providing answers to the most pressing issues in the modern brain diagnostics space.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

The coronavirus pandemic has not only affected the economies of different countries as well as industries around the world, but it has also affected the mental and emotional health of millions of individuals globally.

Field Trip Health, one of the biggest providers of psychedelic therapies globally, recently conducted a survey in the United States focused on both emotional and mental health. The company’s aim was to find out how open-minded respondents were towards including psychedelics into their treatment plans. The survey’s results report that more than 8 out of every 10 individuals who responded experienced at least one symptom of depression. This differs from results of more than 75% of the respondents, who stated that their mental health was OK or better, showing a disparity between self-perception and a potential lack of understanding of mental health metrics.

The survey highlights that only 10% of individuals aged 65 and above self-reported symptoms of depression, which is a small number in comparison with the majority group, which was made up of individuals aged 18 to 24 and had the highest results. In addition to this, one in every four respondents reported that they had thought of harming themselves or had felt that they would be better off dead.

The survey also found that a majority of the participants had turned to coping mechanisms such as drugs to help them deal with negative emotions and thoughts. Other coping mechanisms mentioned included gambling, overeating, porn and alcohol. Reports show that the consumption of alcohol increased by more than 30% since the onset of the pandemic. Despite this, however, more than 40% of the survey participants also relied on the support of a counselor, therapist or mental health professional.

The findings also show that, in comparison with men, women reported worse negative mental health outcomes throughout the pandemic and were more likely to show negative mental health states. This was in addition to bearing the brunt of the negative effects on their financial and professional security. The study results also noted that while 70% of respondents had never used psychedelic substances, more than 30% revealed that they supported the use of these substances in psychedelic-assisted therapies, with more than 20% revealing that they’d like to learn more about psychedelics. Furthermore, 24% of respondents were open to trying psychedelic-assisted therapies.

Currently, more states across the country are moving to legalize the use of these substances in treating various mental conditions. The survey results propose that many may seek these alternative treatment options once they become available.

As public awareness about the medicinal value of psychedelics grows, sector players such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are likely to ramp up their R&D efforts in order to meet the demand when these treatments are finally approved and made available to the general public.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Cannabis reform advocates in Nevada may soon be treated with good news after the state legislature sent a bill that would legalize cannabis consumption lounges to the governor’s desk. Sponsored by Speaker Pro Tempore Steve Yeager, the legislation would create two new cannabis licensing categories, one for retail cannabis consumption lounges and the other for independent cannabis consumption lounges. The bill advanced through a state assembly committee in early April and was passed by the Nevada Assembly in late May before heading to the Senate for final approval.

Last week, the Senate overwhelmingly passed the bill in a 17–3 vote before sending it to Governor Steve Sisolak for his signature. Sisolak has been a major supporter of Nevada’s cannabis industry, and he is expected to sign the bill into law. If he does, Nevada will become the eighth state in the country to legalize cannabis consumption lounges. With tourism being an integral part of Nevada’s economy, stakeholders hope providing safe spaces such as these lounges for cannabis consumption will attract cannabis tourists once the coronavirus pandemic dies down and the country fully opens up.

Under the legislation, existing cannabis retailers will be able to apply for the retail cannabis consumption lounge license and sell cannabis products that can be consumed on-site by adults aged 21 and older. On the other hand, independent lounges would not be allowed to sell cannabis on their own. They would have to contract with existing cannabis retailers to deliver ready-to-consume cannabis products, which the independent lounges would then provide to eligible customers on-site.

The Nevada Cannabis Compliance Board would be tasked with creating regulations for these consumption lounges and collecting fees from license applicants. According to the legislation, retailers that qualify as social equity applicants would be charged reduced fees, with the bill classifying a social-equity applicant as anyone who was adversely affected by anti-cannabis policies in the past. A further amendment to the bill, which was approved by both the House and the Senate, would allow local governments to adopt more restrictive regulations for cannabis consumption lounges within their jurisdictions if desired.

The Nevada Assembly also passed two separate measures: one stipulated that the amount of THC in a person’s blood could not be used to determine whether or not they were impaired while driving, and a second reducing penalties for minors who consume cannabis. Some advocates argued that the THC limit used to determine the level of impairment was arbitrary and lacked sufficient scientific evidence.

With such a progressive approach to cannabis legislation, it may not be long before Nevada catches the attention of companies such as Red White & Bloom Brands Ltd. (CSE: RWB) (OTCQX: RWBYF) which operate on the super-state operator or multistate operator models.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

• Cybin submits first-ever Patent Cooperation Treaty (“PCT”) filing
• By filing a single PCT application, the company simultaneously seeks protection for its proprietary drug treatments in a large number of countries
• Cybin filed the PCT application to provide broad international patent protection of key intellectual property

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to focus on its goal to improve the lives of those suffering from mental illness by changing the expectation of treatment. As part of that mission, the company has filed an international patent application that would provide the potential to obtain patent coverage in 153 countries (https://ibn.fm/Of5wi).

“Technologies gained by Cybin resulting from our strategic acquisition of Adelia Therapeutics, coupled with subsequent research initiatives from our experienced scientific team, have produced Cybin’s first PCT (Patent Cooperation Treaty) filing,” said Cybin CEO Doug Drysdale. “As we progress our R&D and clinical programs, we expect to continue to create and develop innovative therapeutics with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side effects.”

By filing a single international application with the Patent Cooperation Treaty (“PCT”), Cybin can simultaneously seek protection for its proprietary drug treatments in a large number of countries (https://ibn.fm/zTFMK). In addition, the PCT assists applicants in seeking patent protection internationally for their inventions, helps patent offices with their patent-granting decisions, and facilitates public access to a wealth of technical information relating to those inventions.

Cybin filed the PCT application to provide broad international patent protection of key intellectual property in support of the company’s strategic objectives. Those objectives include the company’s three-pillar drug development strategy: creating a novel drug discovery platform and research on the potential efficacy of psychedelic molecules to address unmet mental health needs; efficient drug delivery to enhance dosing control; and a potential novel treatment regimen.

Specifically, the company is working on four drug programs: CYB001, a sublingual psilocybin formulation designed for patients suffering from major depressive disorder; CYB003 and CYB004, both proprietary deuterated psychedelic tryptamines designed for treatment of alcohol-use disorder and other therapy-resistant psychiatric disorders; and CYB005, a phenethylamine-targeting psychiatry and neurology treatment.

Psychedelic therapies are being seriously considered as a novel treatment option for a variety of mental health issues. For decades, psychedelics have been largely ignored because both federal and state laws prohibited the substances. However, a growing body of research is showing evidence of both the efficacy and safety of psychedelic use, and public opinion about the drugs is changing. While psychedelics may feel like a new industry, they actually boast a long history of use within indigenous cultures that stretches back centuries. A paradigm shift has opened the door to new research and development in the field of psychedelic medicine and treatment regimens, and Cybin is leading the way.

Cybin is confident that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

A recent study published in “Neuro-Oncology” has found that brain tumor global histology distribution differs significantly, which suggests inconsistencies in data quality and registration practices.

Researchers examined data from more than 280 cancer registries that took part in the CONCORD-3 study, which was made up of more than 670,000 adults and 67,000 children with brain tumors diagnosed between 2000 and 2014. Some countries were excluded from the analysis as their records didn’t have viable morphology codes.

The study population was made up of more than 600,000 adults, aged between 15 to 99 years, and more than 60,000 children, aged between 0 to 14 years. The researchers defined this population into 11 histology groups for grown-ups and 12 for children.

They then recorded trends for individuals diagnosed in the periods between 2010–14, 2005–09 and 2000–04 by histology group and country, with the main focus being on histology distribution for the 2005–09 period given that the proportions were greater in comparison with the other periods. The researchers found that the proportion of tumors in children diagnosed within the 2005–09 period was under 10% in various countries in Africa and over 30% in the United Kingdom and the United States. These low-grade astrocytomas were classified by the World Health Organization under grade 1 or 2.

On the other hand, while unspecified astrocytomas made up less than 10% of tumors in some countries, with the Russian Federation having the highest rates, high-grade astrocytomas ranged between 10% to 20% elsewhere and under 10% in countries such as the U.S. and Canada. These high-grade astrocytomas were classified by the WHO under grade 3 or 4.

In addition to this, the researchers found that medulloblastomas made up less than 10% of tumors in China and some countries in Africa, with countries such as Taiwan and Jordan having higher rates.

Within the 2005-09 period, researchers discovered that anaplastic and diffuse astrocytomas made up under 10% of tumors in more than 20 countries, with the range being 10% to 19% in nations such as the U.S., Brazil and Argentina. Additionally, the proportion of tumors categorized as glioblastomas were less than than 10% in China and ranged between 50% to 70% in more than 20 European countries and in some countries in North America.

The researchers also found that the proportion of medulloblastomas in children differed greatly between countries, which offset the fraction of low-grade astrocytomas in some countries.

In their report, the investigators noted that the international differences in the histology distribution were significant, adding that they had found evidence that the variation may have been brought about by inconsistencies in the quality of data and the global variations in cancer registration practices.

It is of great concern that brain cancer cases aren’t being captured properly. The concern is that  people who would have benefited from better therapeutic products made by companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) may not benefit since they aren’t in the databases of the medical systems in their countries.

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Irina Nazarova, Brain Scientific’s marketing director, interviewed for Grit Daily, one of the top news hubs for startups, discussing exciting new product developments the company is working on
• BRSF is poised to extend the universe of EEG use cases, expanding possible markets for its disruptive products

Irina Nazarova, marketing director of Brain Scientific (OTCQB: BRSF), was interviewed for Grit Daily News, the top news source on Millennial and Gen Z startups, where she presented the latest work that the company does in the space of neurology medical devices (https://ibn.fm/CeYY3). Nazarova, who has significant marketing experience as the former Editor-in-Chief at the largest entertainment magazine in Russia, discussed with Daniela Elezovic of Grit Daily, the exciting neurological advancements made possible by the work of Brain Scientific and how the company works toward expanding what is possible in neurology space.

Nazarova highlights products that the company has developed in the EEG space: NeuroCap, a ready-to-use and disposable EEG headset that allows any member of medical staff to perform routine EEG testing within minutes, and NeuroEEG, portable, wireless and miniature amplifier. NeuroCap aims to disrupt the current slow and cumbersome EEG testing and bring cost-effective yet high-quality alternatives in what Nazarova describes conservative industry.

Traditionally, the use of EEG was limited to the medical or scientific settings where the device established itself as the gold standard for diagnosing conditions such as epilepsy. However, recent trends open the door for leveraging the power of the device beyond traditional settings to include applications related to our daily experiences such as in education, sleep, e-sports, meditation, and many more. The list of possible applications where EEG could be used is virtually limitless — it can improve any area of our lives.

As Nazarova concludes, the technology does not have boundaries — and Brain Scientific continues to develop breakthroughs that enhance people’s lives.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.